1981
DOI: 10.1002/jso.2930160412
|View full text |Cite
|
Sign up to set email alerts
|

Adrenal adenocarcinomas: Diagnosis and management

Abstract: Thirty-two patients with adrenal adenocarcinoma are reviewed. Eleven of them had symptoms suggestive of a hormonally functional tumor. The median survival in 17 patients who had the primary tumor removed was 13.5 months from the time of surgery, with one patient surviving disease-free 19 years later. The median survival of 11 patients who did not have surgery owing to delays in diagnosis was 7.5 months from the onset of symptoms. Of six patients given O,P'DDD, two patients had objective regression, one partial… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

1984
1984
2008
2008

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(4 citation statements)
references
References 25 publications
0
4
0
Order By: Relevance
“…31,112 Single-agent chemotherapy (carboplatin, 37 cisplatin, 37 or methotrexate 25 ) has been found to be ineffective in terms of tumor response and pain relief. Combination therapies that are associated with varying degrees of success include hydroxyurea with 5-fluorouracil; 5 cisplatin, vinblastine, and bleomycin with concurrent radiotherapy; 6 preoperative cyclophosphamide, vincristine, doxorubicin, and decarbazine together with radiotherapy; 62 vincristine and methotrexate with leucovorin rescue; 37 and ifosfamide and doxorubicin with intrathecal or intraventricular therapy with hydrocortisone, ara-C, and methotrexate. 112 No benefit has been reported with the combination of actinomycin-D, cyclophosphamide, and vincristine, nor with cisplatin and 5-fluorouracil or highdose methotrexate.…”
Section: Neurosurg Focus / Volume 12 / May 2002mentioning
confidence: 99%
“…31,112 Single-agent chemotherapy (carboplatin, 37 cisplatin, 37 or methotrexate 25 ) has been found to be ineffective in terms of tumor response and pain relief. Combination therapies that are associated with varying degrees of success include hydroxyurea with 5-fluorouracil; 5 cisplatin, vinblastine, and bleomycin with concurrent radiotherapy; 6 preoperative cyclophosphamide, vincristine, doxorubicin, and decarbazine together with radiotherapy; 62 vincristine and methotrexate with leucovorin rescue; 37 and ifosfamide and doxorubicin with intrathecal or intraventricular therapy with hydrocortisone, ara-C, and methotrexate. 112 No benefit has been reported with the combination of actinomycin-D, cyclophosphamide, and vincristine, nor with cisplatin and 5-fluorouracil or highdose methotrexate.…”
Section: Neurosurg Focus / Volume 12 / May 2002mentioning
confidence: 99%
“…The malignant characteristics of chor doma lie in their critical location, locally aggressive nature and high recurrence rates, although the course is generally long [72]. This is not so in the young child where there is early development of metastasis, and local aggressive behavior of the lesion is widespread [18,26,37], These tumors comprise 0.7% of all nervous system lesions. Even though the greatest frequency is between the 5th and 7th decades, those that occur in childhood are seen most com monly in the sacral region and later in the lumbar verte bral segments.…”
Section: Menezes/satomentioning
confidence: 99%
“…Vertebral chordo mas are diagnosed relatively early because of symptoms of spinal cord compression [37], Sacral lesions are charac terized by an expansile destructive tumor. The presence of presacral mass and calcification are helpful diagnostic features.…”
Section: Menezes/satomentioning
confidence: 99%
“…Primary tumors of the sacrum included the following: (1) chordoma (two patients), (2) neurosarcoma (one patient), (3) liposarcoma of the pelvic floor (one patient), (4) osteosarcoma of the sacrum and L-4 and L-5 (one patient), (5) chondrosarcoma (one patient), (6) malignant giant-cell tumor of the sacrum (one patient), and (7) angiomyxoma of the sacrum (one patient). Secondary tumors included recurrent rectal cancer (32 patients) and locally advanced or recurrent epidermoid carcinoma of the anorectum (seven patients).…”
Section: Posterior Pelvic Tumorsmentioning
confidence: 99%